Chart 1: Chart for the ongoing monitoring (vital signs, height, weight) of patients during of guanfacine treatment

This chart is designed to support you in the ongoing monitoring of Intuniv® ▼ (guanfacine hydrochloride) prolonged-release tablet treatment in child and adolescent patients with attention-deficit/hyperactivity disorder (ADHD) for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.

As detailed in the Summary of Product Characteristics (SmPC) cardiovascular status in addition to weight should be monitored regularly in patients receiving guanfacine. It is recommended that this chart is used in conjunction with the Intuniv® SmPC **(click here to view)**. Importantly:

- Blood pressure and heart rate (pulse) should be assessed and recorded and assessments should continue on a weekly basis during dose titration and stabilisation and at least every 3 months for the first year, taking into consideration clinical judgement. Six-monthly monitoring should follow thereafter with more frequent monitoring following any adjustment of dose
- Weight, height and body mass index (BMI) should be monitored at the start of treatment and every 3 months during the first year, then 6 monthly taking in to consideration clinical judgement with maintenance of a growth chart

Please download and print this chart prior to your consultation. It will not be possible for you to store any patient-specific information on the website. The completed chart can be documented within the patient's records.

Date of initial assessment:	
Patient name:	
Date of birth:	
Age:	Gender:

	Baseline, prior to beginning guanfacine treatment	Subsequent appointments							
Date of assessment									
Blood pressure									
Heart rate (pulse) (bpm)									
Body weight (kg)									
Height (cm)									
BMI (kg/m^2)									

This chart is intended for use by Healthcare Professionals only, in conjunction with the Intuniv® SmPC
This resource was developed by Takeda as part of a commitment made in the Risk Minimisation Measures for Intuniv®.

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance. Website: www.hpra.ie.
Adverse events should also be reported to Takeda at AE.GBR-IRL@takeda.com.

Version-0015 Date of Approval: July 2022

© Takeda 2022